MIRM
Mirum Pharmaceuticals, Inc.
$117.90
-3.10
(-2.56%)
Mkt Cap
5.95B
Volume
174,868
52W Range
50.25-130
Sector
Healthcare
Beta
0.48
EPS (TTM)
-13.61
P/E Ratio
-168.06
Revenue (TTM)
569.61M
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions. Its lead experimental drug, LIVMARLI, an oral treatment, is currently undergoing trials for progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, and biliary atresia. Furthermore, the company is advancing Volixibat to address intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Founded in 2018, Mirum Pharmaceuticals, Inc. operates from its headquarters in Foster City, California.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 521.31M | 336.89M | 186.37M | 77.06M | 19.14M | 0 | 0 | 0 |
| Net Income | (23.36M) | (87.94M) | (163.41M) | (135.66M) | (83.99M) | (103.27M) | (52.55M) | (17.35M) |
| EPS | -0.47 | -1.85 | -4.00 | -4.01 | -2.77 | -4.09 | -2.29 | -0.75 |
| Free Cash Flow | 54.87M | 9.33M | (91.05M) | (120.41M) | (151.78M) | (89.30M) | (39.64M) | (7.87M) |
| FCF / Share | 1.09 | 0.20 | -2.23 | -3.56 | -5.01 | -3.54 | -1.72 | -0.34 |
| Operating CF | 55.83M | 10.32M | (70.94M) | (120.14M) | (132.76M) | (89.08M) | (39.36M) | (373,000) |
| Total Assets | 842.81M | 670.75M | 646.62M | 352.91M | 294.65M | 240.86M | 146.71M | 51.98M |
| Total Debt | 319.45M | 317.76M | 308.14M | 2.19M | 2.61M | 3.26M | 3.65M | 0 |
| Cash & Equiv | 296.68M | 222.50M | 286.33M | 28.00M | 31.34M | 142.09M | 11.97M | 51.96M |
| Book Value | 314.69M | 225.64M | 248.67M | 142.04M | 120.21M | 172.09M | 130.35M | (10.32M) |
| Return on Equity | -0.07 | -0.39 | -0.66 | -0.96 | -0.70 | -0.60 | -0.40 | N/A |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 159.88M | 148.93M | 133.01M | 127.78M | 111.58M | 99.41M | 90.38M | 77.88M | 69.22M | 69.55M | 47.73M | 37.50M |
| Net Income | (790.15M) | (5.73M) | 2.90M | (5.86M) | (14.68M) | (23.79M) | (14.23M) | (24.64M) | (25.28M) | (35.66M) | (23.59M) | (74.04M) |
| EPS | -13.43 | -0.12 | 0.06 | -0.12 | -0.30 | -0.49 | -0.30 | -0.52 | -0.54 | -0.71 | -0.57 | -1.94 |
| Free Cash Flow | (229.43M) | 5.47M | 39.49M | 11.91M | (2.00M) | (5.09M) | (6.20M) | (14.58M) | 15.20M | (21.62M) | (18.22M) | (17.40M) |
| FCF / Share | -3.90 | 0.11 | 0.68 | 0.24 | -0.04 | -0.11 | -0.13 | -0.31 | 0.32 | -0.46 | -0.44 | -0.46 |
| Operating CF | (228.76M) | 6.07M | 39.68M | 12.04M | (1.96M) | (5.07M) | 3.98M | (3.80M) | 15.21M | (16.62M) | (18.22M) | (17.33M) |
| Total Assets | 890.92M | 842.81M | 785.12M | 725.83M | 690.25M | 670.75M | 667.89M | 660.75M | 651.96M | 646.62M | 650.64M | 443.59M |
| Total Debt | 323.78M | 319.45M | 318.76M | 318.90M | 317.16M | 317.76M | 317.65M | 316.56M | 307.52M | 308.14M | 307.97M | 307.83M |
| Cash & Equiv | 324.91M | 296.68M | 282.02M | 228.12M | 211.82M | 222.50M | 222.97M | 233.25M | 302.84M | 286.33M | 303.06M | 297.23M |
| Book Value | 242.49M | 314.69M | 292.05M | 255.16M | 233.26M | 225.64M | 232.02M | 228.99M | 234.60M | 248.67M | 269.08M | 78.61M |
| Return on Equity | -3.26 | -0.02 | 0.01 | -0.02 | -0.06 | -0.11 | -0.06 | -0.11 | -0.11 | -0.14 | -0.09 | -0.94 |
MIRM News
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mirum Pharmaceuticals: This Liver Disease Juggernaut Just Broadened Its Portfolio
Strength Seen in Mirum Pharmaceuticals (MIRM): Can Its 5.5% Jump Turn into More Strength?
Biotech ETF Index Surges 10% After Rebalance
MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review (Revised)
MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review (Revised)
MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review
Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva
Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)